Kurt Hoffmayer is a Cardiology physician. OpenAlex indexes 188 publications with 1,793 citations (h-index 24).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Industry payments
22 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Boston Scientific CorporationProgram year202512 payments
- Abbott LaboratoriesProgram year202529 payments
- Analog Devices Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
62.9%Beta blocker23.9%Metoprolol Succinate35%Metoprolol Tartrate16%Nadolol16%Sotalol15%Carvedilol10%Bisoprolol Fumarate5%Acebutolol Hcl3%Part D<11 patientsAntiarrhythmic20.7%Flecainide Acetate45%Amiodarone Hcl27%Dofetilide23%Multaq5%Part D<11 patients+ 7 more classes in this area
Blood & clotting
37.1%Factor Xa inhibitor37.1%Eliquis85%Xarelto15%Part D≥117 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2010–2011 per NIH RePORTER. The latest:
- Novel markers of synchrony in the evaluation of cardiac resynchronization therapy
University of California, San Francisco
FY2011$58,682F32HL104727 - Novel markers of synchrony in the evaluation of cardiac resynchronization therapy
University of California, San Francisco
FY2010$60,290F32HL104727
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Impact of artificial intelligence arrhythmia mapping on time to first ablation, procedure duration, and fluoroscopy use
Journal of Cardiovascular Electrophysiology
2024 - Pulsed field ablation versus thermal energy ablation for atrial fibrillation: a systematic review and meta-analysis of procedural efficiency, safety, and efficacy
Journal of Interventional Cardiac Electrophysiology
2023
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Harlan Krumholz, MD
Yale School of Medicine
Scott Solomon, MD
Brigham and Women's Hospital
Eric Topol, MD
Scripps Research Institute (Scripps Research)
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”